News
Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.
A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has a reputation for being the go-to choice for income-focused investors ...
Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...
As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they are.
21h
MedPage Today on MSNPhototherapy Promising as Add-On to Oral Ritlecitinib for VitiligoAdding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...
If approved for wide release, the pill, orforglipron, could shake up the booming GLP-1 market by offering an option that's easier to make and store than the injections that are currently available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results